Quick Answer
Cue Biopharma, Inc. reported Total Revenue of $27.47 million for fiscal year 2025.
Cue Biopharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $27.47M +195.7% |
$9.29M +69.2% |
$5.49M +341.0% |
$1.25M -91.7% |
$14.94M +373.7% |
$3.15M -8.8% |
| Revenue (ASC 606) | $27.47M +195.7% |
$9.29M +69.2% |
$5.49M +341.0% |
$1.25M -91.7% |
$14.94M +373.7% |
$3.15M -8.8% |
| Net Income | -$26.60M +34.6% |
-$40.67M +19.8% |
-$50.73M +4.3% |
-$53.01M -20.0% |
-$44.16M +1.4% |
-$44.78M -22.0% |
| Diluted EPS | -$0.28 +61.1% |
-$0.72 +35.1% |
-$1.11 +25.5% |
-$1.49 -5.7% |
-$1.41 | — |
| Total Assets | $42.21M +31.1% |
$32.19M -47.7% |
$61.53M -32.6% |
$91.28M +9.5% |
$83.40M -16.2% |
$99.53M +39.0% |
| Cash and Equivalents | $27.14M +20.8% |
$22.46M -53.7% |
$48.51M -6.0% |
$51.61M -19.8% |
$64.37M -14.0% |
$74.87M +69.0% |
| Long-Term Debt | — | $0.00 -100.0% |
$4.20M -47.7% |
$8.04M | $0.00 | — |
| Stockholders Equity | $26.43M +51.0% |
$17.50M -52.8% |
$37.09M -43.5% |
$65.68M +0.3% |
$65.49M -17.0% |
$78.91M +44.6% |
| R&D Expense | $37.74M +4.0% |
$36.30M -11.0% |
$40.80M +5.8% |
$38.58M -6.7% |
$41.35M +23.3% |
$33.55M +22.0% |
| Operating Income | -$26.55M +36.0% |
-$41.50M +20.4% |
-$52.15M +2.0% |
-$53.23M -21.8% |
-$43.71M +3.0% |
-$45.04M -22.5% |
| Shares Outstanding | 96.62M +56.3% |
61.82M +30.9% |
47.22M +0.0% |
47.22M +46.6% |
32.20M +6.1% |
30.35M +14.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.15M | -35.6% | -27.3% |
| Revenue (ASC 606) | September 30, 2025 | $2.15M | -35.6% | -27.3% |
| Net Income | September 30, 2025 | -$7.45M | +14.0% | +12.2% |
| Diluted EPS | September 30, 2025 | -$0.07 | +58.8% | +22.2% |
| Total Assets | September 30, 2025 | $31.64M | -29.4% | -22.3% |
| Cash and Equivalents | September 30, 2025 | $11.70M | -63.9% | -57.4% |
| Long-Term Debt | September 30, 2024 | $1.33M | -74.3% | -41.9% |
| Stockholders Equity | September 30, 2025 | $13.25M | -47.8% | -27.1% |
| R&D Expense | September 30, 2025 | $4.75M | -49.3% | -39.9% |
| Operating Income | September 30, 2025 | -$7.59M | +13.8% | +12.0% |
| Shares Outstanding | September 30, 2025 | 77.78M | +29.2% | +1.7% |
- Cue Biopharma, Inc. reported Total Revenue of $27.47 million for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +195.7% in Total Revenue compared to the prior fiscal year.
- Cue Biopharma, Inc. reported Revenue (ASC 606) of $27.47 million for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +195.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Cue Biopharma, Inc. reported Net Income of -$26.60 million for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +34.6% in Net Income compared to the prior fiscal year.
- Cue Biopharma, Inc. reported Diluted EPS of $0.28 per share (loss) for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +61.1% in Diluted EPS compared to the prior fiscal year.
- Cue Biopharma, Inc. reported Total Assets of $42.21 million for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +31.1% in Total Assets compared to the prior fiscal year.
- Cue Biopharma, Inc. reported Cash and Equivalents of $27.14 million for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +20.8% in Cash and Equivalents compared to the prior fiscal year.
- Cue Biopharma, Inc. reported Long-Term Debt of $0.00 for fiscal year 2024.
- Cue Biopharma, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Cue Biopharma, Inc. reported Stockholders Equity of $26.43 million for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +51.0% in Stockholders Equity compared to the prior fiscal year.
- Cue Biopharma, Inc. reported R&D Expense of $37.74 million for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +4.0% in R&D Expense compared to the prior fiscal year.
- Cue Biopharma, Inc. reported Operating Income of -$26.55 million for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +36.0% in Operating Income compared to the prior fiscal year.
- Cue Biopharma, Inc. reported Shares Outstanding of 96.62 million shares for fiscal year 2025.
- Cue Biopharma, Inc. showed an increase of +56.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: